Showing 4 results for Fatty Liver
P Farzanegi, Z Pour Amin, M Habibian,
Volume 8, Issue 1 (4-2014)
Abstract
Abstract
Background and Objective: Fatty liver disease is one of the most common diseases in postmenopausal women. While regular exercise can decrease the complication of this disease, it has not been clearly identified. Thus, we aimed to investigate the effect of 6-weeks of aerobic training on Alanine transaminase, Aspartate Aminotransphrase and Alkaline phosphatase changes in menopausal women.
Material and Methods: In this Semi-empirical study, 20 postmenopausal women were randomly divided into equal experimental and control groups. The experimental group participated in a controlled aerobic training at 40-60 percent of maximal heart rate. The program was the three training sessions per week (45-60 minutes) for six weeks. By being fast for 12 hours, blood samples were taken before and after 6 weeks.
Results: After six weeks, the level of Alanine transaminase, Aspartate Aminotransphrase and Alkaline phosphatase decreased significantly in experimental group (p<0.05), in contrast with control group. Also, there were no significant changes in the baseline characteristic of participants, liver enzymes level and lipid profile between experimental and control groups.
Conclusion: The findings showed that six-weeks of aerobic training can diminish liver enzymes but it has not any effect on lipid level.
Key words: Fatty Liver Disease Menopausal Aerobic Training, Liver Trans-Aminases
Fatemeh Islami ,
Volume 9, Issue 5 (11-2015)
Abstract
Abstract
Background and Objectives: Nonalcoholic fatty liver disease is the most common chronic liver disorder and is also currently considered as the hepatic manifestation of metabolic syndrome. Regular exercise training may decrease fatty liver disease complications, although its impact is not yet clear. This study aimed to evaluate the effects of six weeks of aerobic training on liver enzymes and other factors contributing to metabolic syndrome in young inactive women.
Methods: In this quasi-experimental study, 37 inactive overweight women were randomly divided into an experimental and a control group. The experimental one participated in a controlled aerobic training program (5-minute interval walking) at 65-90% maximum heart rate for 6 weeks, 45-90 minutes per session and 4 sessions per week. Blood samples were taken following 12 hours of fasting, both before and after the training program.
Results: The levels of aspartate aminotransferase and alkaline phosphatase decreased in both groups. Alanine aminotransferase level, weight and waist circumference were significantly decreased in the experimental group following the 6-week exercise training (P<0.05). High-density lipoprotein concentration was significantly increased in both groups. Gamma-glutamyl transferase level was decreased in the experimental group, but increased in the control group. The results showed no significant difference in the basic profile of participants, liver enzymes concentration and lipid profile between the experimental and control group.
Conclusion: Six weeks of aerobic training may help prevent hepatic damage through decreasing serum levels of liver enzymes, anthropometric factors and some metabolic syndrome factors associated with nonalcoholic fatty liver disease.
Keywords: Fatty liver, Aerobic training, Metabolic syndrome, Liver enzyme.
Alireza Barari, Faeghe Dehghani Pour, Ahmad Abdi, Parvin Farzanegi,
Volume 14, Issue 2 (3-2020)
Abstract
ABSTRACT
Background and objectives: Nonalcoholic fatty liver disease (NAFLD) is a chronic hepatic disease characterized by fat accumulation inside hepatocytes. The aim of this study was to evaluate effects of exercise training and resveratrol supplementation on activin A and follistatin levels in rats with NAFLD under a high-fat diet.
Methods: Fifty-six old (40-50 weeks) male Wistar rats were assigned to a healthy control group and seven experimental NAFLD groups: 1. high-fat diet, 2. saline, 3. resveratrol supplementation, 4. continuous exercise, 5. interval exercise, 6. continuous exercise+ resveratrol supplementation and 7. interval exercise+ resveratrol supplementation. Rats in the resveratrol supplementation groups were given 25 mg/kg of body weight intraperitoneal injection of resveratrol daily. Exercises were performed five days a week for eight weeks. Data were analyzed with SPSS (version 21) using one-way analysis of variance (ANOVA) and Tukey's post hoc test at significance of 0.05.
Results: Exercise training and resveratrol supplementation significantly decreased plasma activin A level and increased activin A expression (P<0.05). Plasma level of follistatin was significantly higher in rats under a high-fat diet compared to healthy control animals. All exercise and supplementation groups alone and combined lowered follistatin levels. However, follistatin mRNA expression increased significantly after resveratrol supplementation alone, continuous exercise+ resveratrol supplementation, and interval exercise+ resveratrol supplementation.
Conclusion: Resveratrol has a beneficial effect on activin A and follistatin levels in rats with NAFLD. In addition, resveratrol supplementation combined with exercise training may have greater health benefits for NAFLD patients compared to resveratrol supplementation or exercise training alone.
Keywords: Exercise,
Resveratrol,
Activin A,
Follistatin, Nonalcoholic Fatty Liver Disease.
Zahra Eslami, Yahya Mohammadnajad Panah Kandi, Alireza Norouzi, Abdorreza Eghbal Moghanlou, Mehdi Sheikh Arabi, Vahideh Kazeminejad, Seyedeh Somayeh Hosseini Alarzi, Aref Saeidi, Hamidreza Joshaghani,
Volume 16, Issue 3 (5-2022)
Abstract
Background and objectives: Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease caused by the accumulation of large amounts of fat in the hepatocytes. Given that atorvastatin is effective for treatment of NAFLD, the present study investigated effects of high-fat/fructose diet (HFFD) with atorvastatin on liver enzymes and lipid profile in a NAFLD rat model.
Methods: Thirty-two male Wistar rats were divided into four groups: 1) normal control, 2) HFFD control, 3) HFFD + atorvastatin, and 4) normal + atorvastatin. The groups received HFFD for 15 weeks to induce hepatosteatosis. Atorvastatin was administrated at the dose of 10 mg/kg/day. Lipid profile and liver enzymes were measured after eight weeks of intervention.
Results: Triglyceride, cholesterol, gamma-glutamyl transferase, and aspartate transaminase were significantly reduced in the HFFD + atorvastatin group compared with the HFFD control group. In addition, cholesterol, high-density lipoprotein, alkaline phosphatase, and gamma-glutamyl transferase were significantly increased in the normal + atorvastatin group compared with the normal control group. Low-density lipoprotein increased significantly in the HFFD + atorvastatin group and the normal + atorvastatin group compared with other groups. There was a significant difference in the alanine transaminase levels between the groups taking atorvastatin. In fact, alanine transaminase level was lowest in the normal + atorvastatin group.
Conclusion: Atorvastatin improves the lipid profile and fatty liver and controls liver enzymes. Therefore, it can be used with caution to improve the lipid profile and reduce the complications of NAFLD.
